Oracle and AstraZeneca sign AI deal: October results test AstraZeneca stock

Published on 10/20/2026 at 10:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The Oracle agreement adds an AI angle to AstraZeneca's pipeline. AstraZeneca stock costs EUR 147.93 on October 20, 2026 ahead of October 30 results.

Company events and dates

Oracle and AstraZeneca announced a non-binding AI collaboration on October 20, 2026.
Second-quarter 2026 revenue reached USD 15.384 billion, while net income was USD 2.507 billion.
AstraZeneca stock traded at EUR 147.93 at 10:06 a.m. CEST at Lang & Schwarz on October 20, 2026.
The company scheduled its ESMO management event for October 26, 2026 and its results for October 30, 2026.

Makroaufnahme bunter Tabletten und Kapseln mit glänzenden Wassertropfen — AstraZeneca plc (ISIN GB0009895292) entwickelt und produziert verschreibungspflichtige Tabletten, Kapseln und weitere Arzneiformen, Illustration mit AI erstellt.

AstraZeneca (ISIN GB0009895292) traded at EUR 147.93 at Lang & Schwarz on October 20, 2026 at 10:06 a.m. CEST as the drugmaker announced a non-binding artificial intelligence collaboration with Oracle. The agreement gives investors a fresh technology angle before AstraZeneca's October results.

Oracle deal targets clinical trials

According to Oracle on October 20, 2026, the companies will explore how real-world data, cloud services and AI can help identify clinical-trial candidates and accelerate evidence generation. The initial areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases.

The agreement is non-binding, so it does not yet add a quantified revenue stream. Its value lies in the potential to improve recruitment and connect research data with routine care. That makes execution and measurable outcomes more important than the announcement alone.

What does Q2 mean for earnings?

AstraZeneca's second-quarter 2026 revenue was USD 15.384 billion, up 5 percent at constant exchange rates, while net income attributable to common shareholders was USD 2.507 billion. Basic earnings per share came to USD 1.61. Admirals also reported first-half 2026 revenue of USD 30.672 billion, up 6 percent at constant exchange rates, and core earnings per share of USD 5.21, up 11 percent.

Three dated pipeline signals

On October 11, 2026, AstraZeneca reported a 17.05-meter improvement versus placebo in the HICKORY Phase III trial. On October 15, 2026, its insitro collaboration included a USD 40 million upfront payment. On October 19, 2026, the company said more than 100 abstracts would be presented at ESMO 2026, including data from five pivotal Phase III trials, according to National Law Review.

Two dates shape the next test

AstraZeneca's investor-relations calendar lists an ESMO Meet the Management event for October 26, 2026, followed by its nine-month and third-quarter 2026 results on October 30, 2026. Those dates put the Oracle collaboration alongside clinical data and the next financial update.

Stock context for investors

The London Stock Exchange is AstraZeneca's primary listing, and the company is a FTSE 100 member. The central question is whether pipeline data and digital-health initiatives can support growth while the company converts its second-quarter revenue base into further earnings expansion.

At Lang & Schwarz, AstraZeneca stock was trading at EUR 147.93 on October 20, 2026 at 10:06 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.